Chimeric Antigen Receptors against Cancers and Autoimmune Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 235
Special Issue Editor
Interests: CAR-T cells; melanoma; adoptive cell therapy; cancer vaccination; cancer immunotherapy; solid tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of chimeric antigen receptors (CARs) has marked a new era in cancer immunotherapy. Tremendous clinical advances have been achieved via the use of CAR-T cells against a variety of cancers both in preclinical studies and in clinical trials, most notably against leukemia, lymphoma, and multiple myeloma; these studies have resulted in the FDA and EMA approval of these CAR-T-cell therapies. Nevertheless, approximately 50% of patients treated with these approved CAR products experience relapse or refractory disease that necessitates salvage strategies. Furthermore, in patients with solid tumors, CAR-T-cell infusions have not yet been able to induce complete and durable remission. Very recently, the clinical efficacy of CAR-T cells was also proven in patients with autoimmune diseases.
Due to the rapid evolution of this field, the aim of this Special Issue is to focus on advancements and novel strategies regarding CARs for the therapy of cancer and autoimmune diseases.
Prof. Dr. Niels Schaft
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chimeric antigen receptor (CAR)
- cancer
- autoimmune disease
- solid tumor
- effector cell
- CAR format
- CAR transfer
- tumor microenvironment
- targeted antigen
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
